Anatabine dicitrate 柠檬酸新烟草碱|西域试剂

Anatabine dicitrate 柠檬酸新烟草碱,99.24%

产品编号：Bellancom-19918A| 分子式：C₂₂H₂₈N₂O₁₄| 分子量：544.46

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19918A	￥2500.00	杭州北京（现货）
Bellancom-19918A	￥3500.00	杭州北京（现货）
Bellancom-19918A	￥6500.00	杭州北京（现货）
Bellancom-19918A	￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Anatabine dicitrate 柠檬酸新烟草碱

产品介绍

Anatabine dicitrate 是一种烟草生物碱，可以穿过血脑屏障。Anatabine dicitrate 是一种有效的 α4β2 nAChR 激动剂。Anatabine dicitrate 通过阻止淀粉样蛋白前体蛋白的 β 裂解，抑制 NF-κB 激活，并降低淀粉样 β (Aβ) 的产生。Anatabine dicitrate 具有抗炎作用，可用于神经退行性疾病的研究。

生物活性

Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent α4β2 nAChR agonist. Anatabine dicitrate inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine dicitrate has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment.

体外研究

Anatabine (600 μg/mL; 24 hours; SHSY-5Y cells) treatment shows an inhibition of p65 NF-κB phosphorylation.
Anatabine (500-1000μg/mL; 30 minutes; SHSY-5Y cells) treatment fully prevents the increase in BACE-1 mRNA levels induced by TNF-α. After 24 hours, Anatabine treatment shows a dose-dependent inhibition of BACE-1 protein levels.
Anatabine dose dependently inhibits Aβ_1-40 and Aβ_1-42 with an approximate half maximal inhibitory concentration of 640 μg/mL for both Aβ_1-40 and Aβ_1-42 in 7W CHO cells. Anatabine inhibits sAPPβ secretion without impacting sAPPα suggesting that Anatabine is preventing the β-cleavage of amyloid precursor protein (APP).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	SHSY-5Y cells
Concentration:	600 μg/mL
Incubation Time:	24 hours
Result:	An inhibition of p65 NF-κB phosphorylation was observed.

RT-PCR

Cell Line:	SHSY-5Y cells
Concentration:	500 μg/mL, 1000 μg/mL
Incubation Time:	30 minutes
Result:	Fully prevented the increase in BACE-1 mRNA levels induced by TNF-α.

体内研究
(In Vivo)

Anatabine (0.5-2 mg/kg; intraperitoneal injection; daily; for 4 days; transgenic mouse) treatment significantly lowers brain soluble Aβ_1-40 and Aβ_1-42 levels in a transgenic mouse model of Alzheimer's disease.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Transgenic mice overexpressing the human APP695sw mutation and the presenilin-1 mutation M146L (Tg PS1/APPsw) (50 week-old)
Dosage:	0.5 mg/kg, 2 mg/kg
Administration:	Intraperitoneal injection; daily; for 4 days
Result:	Significantly lowered brain soluble Aβ_1-40 and Aβ_1-42 levels in a transgenic mouse model of Alzheimer's disease.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Transgenic mice overexpressing the human APP695sw mutation and the presenilin-1 mutation M146L (Tg PS1/APPsw) (50 week-old)
Dosage:	0.5 mg/kg, 2 mg/kg
Administration:	Intraperitoneal injection; daily; for 4 days
Result:	Significantly lowered brain soluble Aβ_1-40 and Aβ_1-42 levels in a transgenic mouse model of Alzheimer's disease.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Transgenic mice overexpressing the human APP695sw mutation and the presenilin-1 mutation M146L (Tg PS1/APPsw) (50 week-old)
Dosage:	0.5 mg/kg, 2 mg/kg
Administration:	Intraperitoneal injection; daily; for 4 days
Result:	Significantly lowered brain soluble Aβ_1-40 and Aβ_1-42 levels in a transgenic mouse model of Alzheimer's disease.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (183.67 mM; Need ultrasonic)

DMSO : 30 mg/mL (55.10 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8367 mL	9.1834 mL	18.3668 mL
5 mM	0.3673 mL	1.8367 mL	3.6734 mL
10 mM	0.1837 mL	0.9183 mL	1.8367 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶